IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical ...
Laparoscopic and percutaneous approaches have similar short-term efficacy in treating renal tumors. Laparoscopic (LAP) and CT-guided percutaneous (PERC) cryoablation for renal tumors result in similar ...
IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...
Percutaneous cryoablation may provide a safe and effective treatment option for patients with renal tumors, new findings suggest. David J. Breen, MD, and colleagues from University Hospitals of ...
CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Women with early ...
The Gauteng MEC for Health & Wellness, Nomantu Nkomo-Ralehoko, announced on X (Twitter) that the Steve Biko Academic Hospital ...
PFA was noninferior to cryoablation for first recurrence of atrial tachyarrhythmia in patients with paroxysmal atrial fibrillation. Tissue-selective energy delivery and short application times offer ...
CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- IceCure Medical Ltd. (ICCM) (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results